Clinical Trial

Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Pamiparib combined with Surufatinib as a new neoadjuvant therapy in newly diagnosed patients with advanced ovarian cancer.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-12-06; most recent amendment 2024-11-26.
Status change: Recruiting → Active, Not Recruiting 2024-05-02
Trial Details
NCT Number NCT05652283
Lead Sponsor Bai-Rong Xia
Conditions Ovarian Cancer
Enrollment 37 participants
Start Date 2022-11-06
Primary Completion 2024-05-31 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-27